Insulin, Neurogenetics and Memory in Alzheimer's Disease
1 other identifier
interventional
N/A
1 country
1
Brief Summary
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Oct 1999
Typical duration for phase_2 alzheimer-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 1999
CompletedFirst Submitted
Initial submission to the registry
July 3, 2001
CompletedFirst Posted
Study publicly available on registry
July 5, 2001
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2003
CompletedJanuary 21, 2009
December 1, 2004
July 3, 2001
January 20, 2009
Conditions
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (1)
VA Puget Sound Health Care System
Seattle, Washington, 98108, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
Steven Kahn, M.D.
Sanjay Asthana, M.D.
Alfred Fujimoto, M.D.
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Sponsor Type
- FED
Study Record Dates
First Submitted
July 3, 2001
First Posted
July 5, 2001
Study Start
October 1, 1999
Study Completion
March 1, 2003
Last Updated
January 21, 2009
Record last verified: 2004-12